Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.

Enlivex Therapeutics (ENLV) is a client of RedChip Companies, Inc. ENLV agreed to pay RedChip Companies, Inc. an $8,000 monthly cash fee, beginning in February 2024, plus 25,000 warrants with an exercise price of $3.25 and 25,000 warrants with an exercise price of $4.25, for six month of investor awareness services. All warrants have a term of three years from date of issuance. ENLV also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired September 11 to September 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired October 14 to October 25, 2024, and a one-time $37,500 fee for a national TV ad campaign aired December 4 to December 17, 2024.

Read our full disclosures at: www.redchip.com/legal/disclosures